Rheumatoid Arthritis & Ankylosing Spondylitis

Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This interaction prevents the binding of TNFα to its receptors, thereby inhibiting the biological activity of TNFα (a cytokine protein).

Tmax, subQ: 2 to 6 days; Steady state, subQ: 12 weeks; Bioavailability, subQ: approximately 53%; Elimination Half Life: ∼2 weeks.

specific contraindications have not been determined

B

Excretion in breast milk unknown/not recommended

Upper respiratory tract infection (16%), nasopharyngitis, Bronchitis,Injection site reaction, Viral disease, ALT/SGPT level raised (4% ), AST/SGOT level raised (3% ), Hypertension, Dizziness, Paresthesia.

50 mg administered by subcutaneous (SC) injection once a month. Prior to administration, allow syringe to sit at room temperature for 30 minutes. Rotate the injection site.

Should be stored at 2-8℃